Willkie Farr & Gallagher LLP

General

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Cases265

Challenger50%

Patent Owner50%

NPE50%

willkie-farr

willkie.com

Practice Areas

BiotechMech Eng, ManufCommunications

Top Attorneys

Patrick J. CoyneNeal S. CohenPeter Kinsella

Elite Ratings

DCTPTABCAFC

Ratings

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Experience

Grade

Trend

DCT

PTAB

CAFC

Analytics

Lawyers

Cases

Ratings Trends

Practice Areas

Recent Dockets

Entered	Case	Description
02/21/25	Alnylam Pharmaceuticals Inc v. Pfizer Inc 1:22-CV-00336 ( D. DE )	REDACTED VERSION of [424] Declaration by BioNTech Manufacturing GmbH, BioNTech SE. (Attachments: # [1] Exhibit 6, # [2] Exhibit 7, # [3] Exhibit 8)(Tigan, Jeremy) (Entered: 02/21/2025)
02/21/25	Alnylam Pharmaceuticals Inc v. Pfizer Inc 1:22-CV-00336 ( D. DE )	REDACTED VERSION of [423] Reply Brief by BioNTech Manufacturing GmbH, BioNTech SE. (Tigan, Jeremy) (Entered: 02/21/2025)
02/21/25	Alnylam Pharmaceuticals Inc v. Pfizer Inc 1:22-CV-00336 ( D. DE )	STIPULATION of Dismissal Regarding the '480 Patent by BioNTech Manufacturing GmbH, BioNTech SE. (Raucci, Anthony) (Entered: 02/21/2025)
02/19/25	Curevac Se v. Biontech Se 2:23-CV-00222 ( E.D. VA )	MOTIONS REFERRED to Magistrate Judge: Douglas Miller. [767] MOTION for Protective Order (epri, ) (Entered: 02/19/2025)
02/19/25	Curevac Se v. Biontech Se 2:23-CV-00222 ( E.D. VA )	MOTIONS REFERRED to Magistrate Judge: Douglas Miller. [767] MOTION for Protective Order (epri, ) (Entered: 02/19/2025)
01/29/25	Regeneron Pharmaceuticals Inc v. Celltrion Inc 1:24-CV-00053 ( N.D. WV )	USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025)
01/29/25	Regeneron Pharmaceuticals Inc v. Celltrion Inc 1:24-CV-00053 ( N.D. WV )	OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025)
12/23/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	MOTION in Limine to Exclude Expert Testimony of Dr. Suter Pursuant to Fed. R. Evid. 702 by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024)
12/23/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	BRIEF in Support filed by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY re [274] MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label (CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 12/23/2024) BRIEF in Support filed by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY re [274] MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label (CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 12/23/2024)
12/23/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024)